呼吸器合胞体ウイルス（RSV）治療薬市場レポート：2031年までの動向、予測、競合分析

世界の呼吸器合胞体ウイルス（RSV）治療市場の将来は、パリビズマブとリバビリン市場に機会があり、有望視されています。世界の呼吸器合胞体ウイルス（RSV）治療市場は、2025年から2031年までのCAGRが13.2%で、2031年までに推定34億米ドルに達すると予想されます。この市場の主な促進要因は、呼吸器合胞体ウイルス感染頻度の増加と罹患率の増加です。

• Lucintel社の予測では、治療別では免疫予防薬が予測期間中に最も高い成長を遂げる見込みです。
• 薬剤別では、パリビズマブが最も高い成長が見込まれます。
• 地域別では、北米が予測期間中に最も高い成長が見込まれます。

呼吸器合胞体ウイルス（RSV）治療薬市場の戦略的成長機会

市場はRSV治療ツールの復活によって支配されていますが、いくつかの分野に戦略的成長機会があります。

• ワクチンのさらなる開発：ワクチン研究開発の可能性は、RSV感染を予防するために、幼児を含むすべての集団にとって極めて重要です。効果的な予防接種は商業的に実行可能な選択肢であり、疾病負担と関連治療費の軽減に役立ちます。
• 新しい抗ウイルス薬革新的な抗ウイルス薬に焦点を当てることで、RSVカテゴリーにおける既存の治療法のギャップを埋めることができます。効率的な抗ウイルス薬の導入は、特に重症のRSV患者の回復を促進し、多くの人々に利益をもたらします。
• 小児ヘルスケアにおける成長：RSV治療への関心が高まる中、乳幼児に特化した専門センターや管理計画など、小児医療施設を改善する機会があります。
• 診断の進歩：最新の診断ツールを導入することで、患者のRSVの早期発見が容易になり、早期治療と治療成績の向上が期待できます。
• 教育と啓発プログラム：的を絞ったメッセージや啓発キャンペーンを開発することで、介護者やヘルスケアプロバイダーがRSVを特定・管理しやすくなり、早期管理や入院が容易になります。

これらの成長機会は、呼吸器合胞体ウイルス（RSV）治療市場を改善し、予防・治療対策を強化し、最終的に患者の転帰を改善するために重要です。

呼吸器合胞体ウイルス（RSV）治療薬市場の促進要因・課題

RSV治療薬は、その開発と成長を促進する、あるいは課題となる多くの要因に直面しているため、非常に複雑です。

呼吸器合胞体ウイルス（RSV）治療薬市場を牽引する要因は以下の通り：

• RSVに対するヘルスケアの専門家だけでなく、社会的にも呼吸器合胞体ウイルスとそのハイリスクグループへの影響に対する関心が高まっています。そのため、効果的な治療法や予防法に対する需要が増加しています。
• 医学研究の進歩：医学研究の進歩は常に無為無策であり、モノクローナル抗体やワクチンなど、RSV管理のための治療の選択肢が増える見込みです。
• 政府の支援と資金援助：RSV疾患に焦点を当てたプログラムや、適切な治療とワクチン接種の開発を促進する効果的な公衆衛生アプローチに対する政府の支援と資金援助が大幅に増加しています。
• RSVの発生率の増加：特に乳幼児や高齢者におけるRSVの発生率の高さから、健康上の危険に対する効果的な治療および予防法の開発が急務となっています。
• ヘルスケアにおける世界な連携：医療従事者、産業界、その他の利害関係者間の革新的で協力的なアプローチにより、RSV疾患に対するさまざまな戦略開発が加速しています。

呼吸器合胞体ウイルス（RSV）治療市場における課題は以下の通り：

• 規制上のハードル：新しい治療法やワクチンの承認に必要な臨床エビデンスを集め、官僚的な規制プロセスを通過することは、開発者にとって大きな課題であり、市場参入のタイミングに影響を与える可能性があります。
• 研究開発コスト：RSVの新規治療薬の研究開発には多額の費用がかかるため、特に中小企業にとっては法外なコストがかかり、革新的な治療法の市場が制限される可能性があります。
• 一般市民の認識と意識：RSVの認知度は向上していますが、予防や治療戦略に影響を及ぼす誤解がまだ存在します。効果的な教育努力が引き続き必要です。

効果的な市場促進要因および制約は、RSV治療薬市場において重要な役割を果たし、新薬開発に影響を与えます。これらの課題に対処することは、患者の健康を改善し、RSV管理を新たなレベルに引き上げることを目指すすべての利害関係者の主要な目標です。

目次

第1章 エグゼクティブサマリー

第2章 世界の呼吸器合胞体ウイルス（RSV）治療薬市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2019年から2031年までの市場動向と予測分析

• マクロ経済動向（2019～2024年）と予測（2025～2031年）
• 世界の呼吸器合胞体ウイルス（RSV）治療市場の動向（2019年～2024年）と予測（2025年～2031年）
• 薬剤別：世界の呼吸器合胞体ウイルス（RSV）治療市場
  • パリビズマブ
  • リバビリン
  • その他
• 治療別：世界の呼吸器合胞体ウイルス（RSV）治療市場
  • 免疫予防
  • 支持療法
  • 抗ウイルス薬
• 投与形態別：世界の呼吸器合胞体ウイルス（RSV）治療薬市場
  • オーラル
  • 注射可能
  • その他
• 患者タイプ別：世界の呼吸器合胞体ウイルス（RSV）治療市場
  • 小児
  • 成人

第4章 2019年から2031年までの地域別市場動向と予測分析

• 地域別：世界の呼吸器合胞体ウイルス（RSV）治療市場
• 北米の呼吸器合胞体ウイルス（RSV）治療市場
• 欧州の呼吸器合胞体ウイルス（RSV）治療薬市場
• アジア太平洋地域の呼吸器合胞体ウイルス（RSV）治療市場
• その他地域の呼吸器合胞体ウイルス（RSV）治療市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 治療薬別：世界の呼吸器合胞体ウイルス（RSV）治療市場の成長機会
  • 治療別：世界の呼吸器合胞体ウイルス（RSV）治療薬市場の成長機会
  • 投与形態別：世界の呼吸器合胞体ウイルス（RSV）治療薬市場の成長機会
  • 患者タイプ別：世界の呼吸器合胞体ウイルス（RSV）治療市場の成長機会
  • 地域別：世界の呼吸器合胞体ウイルス（RSV）治療市場の成長機会
• 世界の呼吸器合胞体ウイルス（RSV）治療薬市場における新たな動向
• 戦略分析
  • 新製品開発
  • 世界の呼吸器合胞体ウイルス（RSV）治療薬市場の生産能力拡大
  • 世界の呼吸器合胞体ウイルス（RSV）治療薬市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• Johnson & Johnson
• F. Hoffmann-La Roche
• Merck & Co.
• AbbVie
• Novartis
• Sanofi
• AstraZeneca
• Abbott Laboratories
• GlaxoSmithKline
• Gilead Sciences

The future of the global respiratory syncytial virus (RSV) therapeutic market looks promising with opportunities in the palivizumab and ribavirin markets. The global respiratory syncytial virus (RSV) therapeutic market is expected to reach an estimated $3.4 billion by 2031 with a CAGR of 13.2% from 2025 to 2031. The major drivers for this market are the increase in the frequency of respiratory syncytial virus infection and the increasing disease rate.

• Lucintel forecasts that, within the treatment category, immune prophylaxis is expected to witness the highest growth over the forecast period.
• Within the drug category, palivizumab is expected to witness the highest growth.
• In terms of regions, North America is expected to witness the highest growth over the forecast period.

Gain Valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Respiratory Syncytial Virus (RSV) Therapeutic Market

There are emerging trends in the respiratory syncytial virus (RSV) therapeutic market that are changing the market as they are propelled by new developments in treatment, prevention, and awareness.

• Advancement in Monoclonal Antibodies: New monoclonal antibody treatment modalities are emerging, which are expected to assist in reducing RSV-related hospital visits, mostly among high-risk groups like children and the elderly. These therapies are becoming more popular because they effectively protect against the RSV virus.
• Vaccine Development Initiatives: There is a heightened need for the development of vaccines, with many vaccine candidates currently in clinical phases. A focus on pregnant women and infants is being leveraged to develop vaccination strategies that aim to provide more robust immunity in the early months of life when the risk of infection is high.
• Integration of Telemedicine: Telemedicine is helping to identify and treat RSV in the early stages, as symptoms can be tracked remotely, even in areas with poorly facilitated medical care.
• Increased Public Awareness Campaigns: More effective public health campaigns have resulted in greater awareness of what RSV is, what causes it, and other relevant information regarding its prevention. Training caregivers to recognize and manage RSV is critical to improving the timing of treatment.
• Integration Involving Pharmaceutical Corporations and Academic Institutions: Recent trends illustrate how pharmaceutical institutions, academia, and government organizations are forging partnerships, which speed up the development of new therapies and vaccines, further enhancing the response to RSV.

These trends are transforming the current treatment of patients with RSV by improving and expanding treatment options, enhancing prevention, and fostering collaboration among key players in the market, thus improving the condition of patients affected by this virus.

Recent Developments in the Respiratory Syncytial Virus (RSV) Therapeutic Market

The respiratory syncytial virus (RSV) therapeutic market has undergone several important changes that improve the control and management of the infectious disease.

• Effective Therapeutic Methods: Monoclonal Antibodies: Clinical trials and recent approvals of monoclonal antibody therapy demonstrate promising results, with a potential reduction in infant RSV hospitalizations. These treatments accommodate high-risk populations.
• Vaccines Being Developed: Several vaccine candidates that could offer protection against RSV for either infants or pregnant women are currently in clinical trials. These findings are important for preventing the worst forms of the disease.
• Improved Diagnostic Tools: Emerging diagnostic technologies have improved the timeliness and accuracy of RSV detection, aiding in the quick management of infections and reducing complications associated with delayed attention.
• Growing Attention Towards the Care of the Young: Healthcare systems are currently addressing pediatric RSV care and developing new practices and management strategies for babies and younger children, who are the most susceptible to the virus.
• United Research Partnerships: These partnerships ensure that viable RSV treatment alternatives and vaccine development processes are accelerated by the participation of stakeholders.

Such changes indicate a transition within the RSV therapeutic landscape, which is now more responsive to the demand for treatment, prevention, and improved clinical outcomes through better methods.

Strategic Growth Opportunities for Respiratory Syncytial Virus (RSV) Therapeutic Market

Although the market is dominated by the resurgence of RSV therapeutic tools, there are strategic opportunities for growth in several areas.

• Further Development of Vaccines: The possibilities in vaccine research and development are crucial for all population groups, including the very young, to prevent RSV infections. Effective immunizations are commercially viable options that help reduce the disease burden and related treatment costs.
• New Antiviral Medicines: Focusing on innovative antiviral medications can fill the gap left by existing treatments in the RSV category. The introduction of efficient antivirals will benefit many, particularly by enhancing the recovery of patients with severe RSV symptoms.
• Growth in Pediatric Healthcare: As RSV treatment is a growing concern, there is an opportunity to improve pediatric care facilities, such as specialized centers and management plans that focus on infants and toddlers.
• Advancements in Diagnostics: The acquisition and incorporation of modern diagnostic tools will facilitate the early detection of RSV in patients, enabling earlier treatment and better outcomes.
• Education and Awareness Programs: Developing targeted messages and awareness campaigns will help caregivers and healthcare providers in identifying and managing RSV, thereby facilitating its early management and hospitalization.

These growth opportunities are significant for improving the respiratory syncytial virus (RSV) therapeutic market and enhancing preventive and treatment measures, ultimately improving patient outcomes.

Respiratory Syncytial Virus (RSV) Therapeutic Market Driver and Challenges

The RSV therapeutic is quite complex because it faces many factors that either foster its development and growth or challenge it.

The factors responsible for driving the respiratory syncytial virus (RSV) therapeutic market include:

• Increased Awareness of RSV: This is owing to the increasing attention given by both healthcare professionals as well as the society concerning RS virus and its implications for high-risk groups. Therefore, demand for effective therapy and prevention approaches is on the rise.
• Advancements in Medical Research: Advancement in medical research is always inaction and more options for treatment such as monoclonal antibodies and vaccines are in prospect for RSV management.
• Government Support and Funding: There has been a substantial increase in government support and funding for programs focused on RSV disease and effective public health approaches helping to promote the development of adequate treatment and vaccination.
• Rising Incidence of RSV: The high incidence of RSV in infants and elderly populations particularly creates a critical need for the development of effective treatment and prevention approaches against the health dangers entailed.
• Global Collaboration in Healthcare: The innovative and collaborative approaches among stakeholders such as health practitioners, industry and other stakeholders have been speeding up the development of different strategists for RSV disease.

Challenges in the respiratory syncytial virus (RSV) therapeutic market are:

• Regulatory Hurdles: Assembling the necessary clinical evidence and navigating bureaucratic regulatory processes for the approval of new treatments and vaccines is a major challenge for developers, which can affect the timing of market entry.
• Cost of Research and Development: The high costs involved in the research and development (R&D) of new therapeutic medicines for RSV can be prohibitively expensive, particularly for smaller firms, which limits the market for innovative solutions.
• Public Perception and Awareness: While awareness of RSV has increased, there are still misconceptions about the disease that affect prevention and treatment strategies. There is a continued need for effective educational efforts.

The effective market drivers and constraints play a significant role in the RSV therapeutic market, affecting the development of new drugs. Addressing these challenges is the primary goal of all stakeholders who aim to improve patient health and bring RSV management to a new level.

List of Respiratory Syncytial Virus (RSV) Therapeutic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies respiratory syncytial virus (RSV) therapeutic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the respiratory syncytial virus (RSV) therapeutic companies profiled in this report include-

• Johnson & Johnson
• F. Hoffmann-La Roche
• Merck & Co.
• AbbVie
• Novartis
• Sanofi
• AstraZeneca
• Abbott Laboratories
• GlaxoSmithKline
• Gilead Sciences

Respiratory Syncytial Virus (RSV) Therapeutic by Segment

The study includes a forecast for the global respiratory syncytial virus (RSV) therapeutic market by drug, treatment, dosage form, patient type, and region.

Respiratory Syncytial Virus (RSV) Therapeutic Market by Drug [Analysis by Value from 2019 to 2031]:

• Palivizumab
• Ribavirin
• Others

Respiratory Syncytial Virus (RSV) Therapeutic Market by Treatment [Analysis by Value from 2019 to 2031]:

• Immune Prophylaxis
• Supportive Care
• Antiviral Medications

Respiratory Syncytial Virus (RSV) Therapeutic Market by Dosage Form [Analysis by Value from 2019 to 2031]:

• Oral
• Injectable
• Other

Respiratory Syncytial Virus (RSV) Therapeutic Market by Patient Type [Analysis by Value from 2019 to 2031]:

• Pediatrics
• Adults

Respiratory Syncytial Virus (RSV) Therapeutic Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Respiratory Syncytial Virus (RSV) Therapeutic Market

Recent developments in the respiratory syncytial virus (RSV) therapeutic market have been driven by increased knowledge and efforts to address therapeutic gaps, particularly among vulnerable populations such as children and the elderly. Countries like the United States, China, Germany, India, and Japan are actively engaging in research and development to provide solutions for the RSV threat. These developments include new, more effective therapies, advances in diagnostics, and improved prophylactic measures, all of which help reduce the burden of the virus and change the outlook for RSV management in the coming years.

• United States: In the United States, several novel RSV treatments are either in clinical trials or already available. Recently, the FDA granted breakthrough therapy designation to monoclonal antibodies targeting RSV, aimed at high-risk patients, demonstrating the need for effective alternatives. Additionally, public health initiatives are working to increase the use of vaccination in babies. The growing attention to antiviral drugs and combination therapies in RSV research and development is also encouraging. Furthermore, the approach to RSV treatment is shifting from disease management to prevention and treatment.
• China: China is making significant progress in developing the RSV therapeutic sector, supported by increased research investment and foreign pharmaceutical firms operating in the country. Some local biotech companies are now involved in developing RSV vaccines and antiviral drugs, driven by the need for improved nursing care for RSV-infected children. Moreover, changes are being made in raising awareness about RSV prevention and treatment among the population. The use of traditional Chinese medicine in combination with standard medicine is also being investigated to improve outcomes. These efforts indicate a growing commitment to improving care for RSV-infected children.
• Germany: In Germany, several clinical trials are exploring new and innovative therapeutic approaches for RSV, such as monoclonal antibodies and antivirals. Key health authorities in Germany are overseeing research focused on high-risk populations, including premature infants and the elderly. Additionally, considerable attention is being given to vaccine development. Educational resources are being utilized in collaboration with healthcare institutions to increase understanding and improve screening for RSV. The use of new-generation technologies is expected to enhance diagnosis and treatment, minimizing hospital stays for RSV patients.
• India: The RSV market in India is maturing, with increasing R&D activity. In recent years, government agencies and private companies have focused on developing effective prophylactic and therapeutic approaches. More healthcare practitioners are recognizing the significance of RSV, leading to better management of the disease. Additionally, community health initiatives will play a key role in educating caregivers about how RSV can be prevented. These initiatives are particularly important in minimizing the RSV disease burden on young children, especially in areas with limited healthcare infrastructure.
• Japan: Japan is making steady progress in the RSV market, with ongoing vaccine development and new antiviral treatment options emerging. Japanese pharmaceutical companies have been conducting more clinical studies of modern monoclonal antibodies and promising vaccine candidates. The government supports these initiatives through funding and favorable legal conditions, recognizing the need for effective RSV management. Furthermore, healthcare providers are considering early treatment with antibiotics for children diagnosed at risk for RSV. Public health programs are also being implemented to reduce RSV infection rates by educating caregivers about prevention.

Features of the Global Respiratory Syncytial Virus (RSV) Therapeutic Market

Market Size Estimates: Respiratory syncytial virus (RSV) therapeutic market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecasts (2025 to 2031) by various segments and regions.

Segmentation Analysis: Respiratory syncytial virus (RSV) therapeutic market size by various segments, such as by drug, treatment, dosage form, patient type, and region in terms of value ($B).

Regional Analysis: Respiratory syncytial virus (RSV) therapeutic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drugs, treatments, dosage forms, patient types, and regions for the respiratory syncytial virus (RSV) therapeutic market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the respiratory syncytial virus (RSV) therapeutic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the respiratory syncytial virus (RSV) therapeutic market by drug (palivizumab, ribavirin, and others), treatment (immune prophylaxis, supportive care, and antiviral medications), dosage form (oral, injectable, and other), patient type (pediatrics and adults), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Respiratory Syncytial Virus (RSV) Therapeutic Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Respiratory Syncytial Virus (RSV) Therapeutic Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Respiratory Syncytial Virus (RSV) Therapeutic Market by Drug
  • 3.3.1: Palivizumab
  • 3.3.2: Ribavirin
  • 3.3.3: Others
• 3.4: Global Respiratory Syncytial Virus (RSV) Therapeutic Market by Treatment
  • 3.4.1: Immune Prophylaxis
  • 3.4.2: Supportive Care
  • 3.4.3: Antiviral Medications
• 3.5: Global Respiratory Syncytial Virus (RSV) Therapeutic Market by Dosage Form
  • 3.5.1: Oral
  • 3.5.2: Injectable
  • 3.5.3: Other
• 3.6: Global Respiratory Syncytial Virus (RSV) Therapeutic Market by Patient Type
  • 3.6.1: Pediatrics
  • 3.6.2: Adults

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Respiratory Syncytial Virus (RSV) Therapeutic Market by Region
• 4.2: North American Respiratory Syncytial Virus (RSV) Therapeutic Market
  • 4.2.1: North American Market by Drug: Palivizumab, Ribavirin, and Others
  • 4.2.2: North American Market by Treatment: Immune Prophylaxis, Supportive Care, and Antiviral Medications
• 4.3: European Respiratory Syncytial Virus (RSV) Therapeutic Market
  • 4.3.1: European Market by Drug: Palivizumab, Ribavirin, and Others
  • 4.3.2: European Market by Treatment: Immune Prophylaxis, Supportive Care, and Antiviral Medications
• 4.4: APAC Respiratory Syncytial Virus (RSV) Therapeutic Market
  • 4.4.1: APAC Market by Drug: Palivizumab, Ribavirin, and Others
  • 4.4.2: APAC Market by Treatment: Immune Prophylaxis, Supportive Care, and Antiviral Medications
• 4.5: ROW Respiratory Syncytial Virus (RSV) Therapeutic Market
  • 4.5.1: ROW Market by Drug: Palivizumab, Ribavirin, and Others
  • 4.5.2: ROW Market by Treatment: Immune Prophylaxis, Supportive Care, and Antiviral Medications

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Respiratory Syncytial Virus (RSV) Therapeutic Market by Drug
  • 6.1.2: Growth Opportunities for the Global Respiratory Syncytial Virus (RSV) Therapeutic Market by Treatment
  • 6.1.3: Growth Opportunities for the Global Respiratory Syncytial Virus (RSV) Therapeutic Market by Dosage Form
  • 6.1.4: Growth Opportunities for the Global Respiratory Syncytial Virus (RSV) Therapeutic Market by Patient Type
  • 6.1.5: Growth Opportunities for the Global Respiratory Syncytial Virus (RSV) Therapeutic Market by Region
• 6.2: Emerging Trends in the Global Respiratory Syncytial Virus (RSV) Therapeutic Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Respiratory Syncytial Virus (RSV) Therapeutic Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Respiratory Syncytial Virus (RSV) Therapeutic Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Johnson & Johnson
• 7.2: F. Hoffmann-La Roche
• 7.3: Merck & Co.
• 7.4: AbbVie
• 7.5: Novartis
• 7.6: Sanofi
• 7.7: AstraZeneca
• 7.8: Abbott Laboratories
• 7.9: GlaxoSmithKline
• 7.10: Gilead Sciences